Podcasts about Population health

For too long, the narrative around men's health has been one of silence, denial, and “toughing it out.” That needs to change. Basketball legend Alonzo Mourning and Dr. Jonathan Fialkow, cardiologist and Chief Medical Executive of Population Health, Value and Primary Care for Baptist Health, break that silence with an honest, emotional, and empowering discussion about early detection, lifestyle changes, and the mindset it takes to fight back. Mourning shares his personal battles with kidney disease and prostate cancer, and why showing up for your health is the ultimate act of strength, not weakness. The session also features powerful audience Q&A moments that highlight real-life struggles, stories, and support. Listen now to hear life-saving insights and help change the way we talk about men's health — for good.Host:Jonathan Fialkow, M.D., Cardiologist, Chief Medical Executive of Population Health, Value and Primary Care at Baptist HealthGuest:Alonzo Mourning, Professional Basketball Hall of Famer and Community Activist

As hospitals and health systems continue to evolve in value-based care, optimizing the post-acute recovery process has become a top priority. In this episode of Value-Based Care Insights, Diane Shifley, Assistant Vice President of Population Health and Post-Acute Services at a major Chicago health system joins us to discuss how robust transitions-in-care programs can drive better patient outcomes. She shares insights on the critical role of early patient evaluation—whether at hospital admission or pre-surgery—in shaping effective transitions. We explore how transitional care models that include post-acute facilities and home care can reduce readmission rates, improve patient satisfaction, and control post-acute costs. This episode offers actionable strategies to strengthen your transitions-in-care to support patients through successful recovery.

As hospitals and health systems continue to evolve in value-based care, optimizing the post-acute recovery process has become a top priority. On this episode Dan is joined by Diane Shifley, Assistant Vice President of Population Health and Post-Acute Services at a major Chicago health system to discuss how robust transitions-in-care programs can drive better patient outcomes. She shares insights on the critical role of early patient evaluation—whether at hospital admission or pre-surgery—in shaping effective transitions. They explore how transitional care models that include post-acute facilities and home care can reduce readmission rates, improve patient satisfaction, and control post-acute costs. This episode offers actionable strategies to strengthen your transitions-in-care to support patients through successful recovery. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode of the NASP Podcast, Sheila Arquette, President & CEO  of NASP, speaks with Dr Andrew Lindsley, US Medical Director at  Amgen and Dr Ash Davé, Director, Medical Value and Population  Health at Amgen, to discuss TEZSPIRE® (tezepelumab-ekko). 

Today, we're speaking to Dr Cini Bhanu, GP and Academic Clinical Lecturer in the Primary Care and Population Health Department at University College London. Title of paper: Antidepressants and risk of postural hypotension: a self-controlled case series study in UK primary careAvailable at: https://doi.org/10.3399/BJGP.2024.0429Antidepressants are associated with postural hypotension (PH). This is not widely recognised in general practice, where antihypertensives are considered the worst culprits. The present study examined >21 000 older adults and found a striking increased risk of PH with use of all antidepressants (over a four- fold risk with SSRIs) in the first 28 days of initiation. TranscriptThis transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.Speaker A00:00:00.480 - 00:00:56.990Hello and welcome to BJGP Interviews. My name is Nada Khan and I'm one of the associate editors of the bjgp. Thanks for listening to this podcast today.In today's episode, we're speaking to Dr. Cini Banu, who is a GP in an academic clinical lecturer based in the Department of Primary Care and Population Health at University College London.We're here to talk about her recent paper in the BJGP titled Antidepressants and Risk of Postural Hypertension, A Self Controlled Case Series Study in UK Primary Care. So, hi Cinny, it's really nice to meet you today.I guess this is an interesting area to cover, especially as the prescribing rates for some antidepressant medications are increasing.But I don't know what your feeling is, but I'm not sure if many GPs would actually know that antidepressants are associated with poison postural hypertension. So, yeah, talk us through that.Speaker B00:00:57.310 - 00:01:18.350Yeah, so I think that's one of the reasons this study is so important.So definitely from conversations that I've had with gps that I work with and it's not commonly recognized that postural hypotension is associated with antidepressants, though it is by geriatricians, for example, where it's very.Speaker A00:01:18.350 - 00:01:41.850Well recognized and in this study used a big database to look at the risk of new postural hypertension associated with the use of antidepressants in people aged over 60.I guess there's quite a lot of in depth stuff in the methods, but I guess just for a summary for people who are interested in what you did, do you mind just sort of going over it at sort of like a high level?Speaker B00:01:41.850 - 00:02:54.200Yeah, yeah. So we looked at a big database, what we call a routine primary care database called imrd.And essentially this captures data from software that gps use like EMIS and Vision System and captures a whole load of information like problems, symptoms and prescriptions. So we went into this database and identified everyone over the age of 60 that might be eligible during our study period.And for this we looked at people that were contributing at least one full year of data between 2010 and 2018. And then within that we identified people with a first diagnosis of postural hypotension.And then again we made subgroups according to people who had this diagnosis but also had a first prescription of a new antidepressant during that time.And what we were interested in, and the methodology is called a self controlled case series, we weren't interested in who got postural Hypotension, because everyone was a case, but rather...

Today's episode of the Faculty Factory Podcast explores strategies for embracing a new career challenge or retirement itself. This broadcast features a recording from a recent lecture led by Faculty Factory Podcast host Kimberly Skarupski, PhD, MPH. Dr. Skarupski is Associate Vice Provost, Leadership Development, in the Office of Faculty Affairs with UTMB Health in Galveston, Texas. She is a tenured Professor in the Department of Internal Medicine, Division of Geriatrics in the John Sealy School of Medicine and in the Department of Epidemiology in the School of Public and Population Health. If you'd like to see the slides from the lecture that this podcast is based on, you can access them here. More Faculty Factory Resources: https://facultyfactory.org/ 

CUNY recently lost federal funding for more than 70 research grants. Denis Nash, professor of epidemiology at the CUNY Graduate School of Public Health and Health Policy and executive director of CUNY's Institute for Implementation Science in Population Health, talks about the funding he recently lost on research related to COVID vaccine uptake, plus comments on the changes coming to how the COVID vaccine is rolled out for the next season.

New York City's CUNY system  recently lost federal funding for more than 70 research grants.On Today's Show:Denis Nash, professor of epidemiology at the CUNY Graduate School of Public Health and Health Policy and executive director of CUNY's Institute for Implementation Science in Population Health, talks about the funding he recently lost on research related to COVID vaccine uptake, plus comments on the changes coming to how the COVID vaccine is rolled out for the next season.

Today, we're speaking to Dr Steve Bradley, GP and Senior Clinical Lecturer based within the School of Medicine and Population Health at the University of Sheffield.Title of paper: General practice chest X-ray rate is associated with earlier lung cancer diagnosis and reduced all-cause mortality: a retrospective observational studyAvailable at: https://doi.org/10.3399/BJGP.2024.0466It is known that there is wide variation in the use of chest X-ray (CXR) by general practices, but previous studies have provided conflicting evidence as to whether greater utilisation of them leads to lung cancer being diagnosed at an earlier stage and improves survival. This observational study analysed data from the English national cancer registry on CXR rates for individual general practices, along with stage and survival outcomes; it found earlier stage at diagnosis and improved survival for patients diagnosed with cancer at practices that used the test more frequently. Increasing use of CXR by GPs for symptomatic patients, particularly by focusing on practices that use the test infrequently, could improve lung cancer outcomes.TranscriptThis transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.Speaker A00:00:00.640 - 00:01:06.820Hello and welcome to BJGP Interviews. I'm Nada Khan and I'm one of the Associate Editors at the Journal. Thanks for taking the time today to listen to this podcast.In today's episode, we're talking to Dr. Steve Bradley. Steve is a GP and senior clinical Lecturer based within the School of Medicine and Population Health at the University of Sheffield.Early diagnosis of cancer has been an area of research that is Steve's real strength. And we're here to discuss his recent paper here in the BJJP titled General Practice.Chest X Ray Rate is Associated with Earlier Lung Cancer Diagnosis and Reduced All Cause Mortality A Retrospective Observational Study. Hi, Steve, Great to speak again and to talk through this paper.I suppose I want to start by saying that, yes, we know that earlier diagnosis of cancer is a good thing because it can lead to earlier stages of diagnosis and treatment. And you start the paper with a short discussion about screening for lung cancer.But talk us through why this, this alone won't solve delays in lung cancer diagnosis and what else we need to be doing.Speaker B00:01:07.540 - 00:02:14.620So, yeah, this context is really important because screening is a hugely important development and the UK has led in many ways on lung cancer screening using low dose ct. And this, we hope is going to be very, very beneficial for patients.But it would be a mistake to think that this is going to solve the problem of lung cancer. And there's a few reasons for that.One is that only about half of people who get lung cancer would have been eligible for screening because screening concentrates on the highest risk population. And also we know that only about half of people who are invited for screening actually choose to participate in screening.So the upshot for general practice really is that most patients are still going to be coming through by symptoms and in the same way.So screening is good news in terms of lung cancer detection, but we still need to do as well as we can in terms of picking these patients up through symptomatic pathways. And actually, this is something we touched on in an editorial for BJGP about a year or 18 months ago, I think.Speaker A00:02:15.020 -...

JCO PO author Dr. Dean A. Regier at the Academy of Translational Medicine, University of British Columbia (UBC), and the School of Population and Public Health, BC Cancer Research Institute shares insights into his JCO PO article, “Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation.” Host Dr. Rafeh Naqash and Dr. Regier discuss the real-world clinical effectiveness and cost-effectiveness of multigene panels compared with single-gene BRAF testing to guide therapeutic decisions in advanced melanoma. Transcript Dr. Rafeh Naqash:Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center in the University of Oklahoma. Today, we are excited to be joined by Dr. Dean A. Regier, Director at the Academy of Translational Medicine, Associate Professor at the School of Population and Public Health, UBC Senior Scientist at the British Columbia Cancer Research Institute, and also the senior author of the JCO Precision Oncology article entitled "Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation." At the time of this recording, our guest's disclosures will be linked in the transcript. Dean, welcome to our podcast and thank you for joining us today. Dr. Dean Regier:Thank you. I'm delighted to be here. Dr. Rafeh Naqash:So, obviously, you are from Canada, and medicine, or approvals of drugs to some extent, and in fact approvals of gene testing to some extent is slightly different, which we'll come to learn about more today, compared to what we do in the US—and in fact, similarly, Europe versus North America to a large extent as well. Most of the time, we end up talking about gene testing in lung cancer. There is a lot of data, a lot of papers around single-gene panel testing in non-small cell lung cancer versus multigene testing. In fact, a couple of those papers have been published in JCO PO, and it has shown significant cost-effectiveness and benefit and outcomes benefit in terms of multigene testing. So this is slightly, you know, on a similar approach, but in a different tumor type. So, could you tell us first why you wanted to investigate this question? What was the background to investigating this question? And given your expertise in health economics and policy, what are some of the aspects that one tends or should tend to understand in terms of cost-effectiveness before we go into the results for this very interesting manuscript? Dr. Dean Regier:Yeah, of course, delighted to. So, one of the reasons why we're deeply interested in looking at comparative outcomes with respect to single- versus multigene testing— whether that's in a public payer system like Canada or an insurer system, a private system in the United States— is that the question around does multigene versus single-gene testing work, has not typically tested in randomized controlled trials. You don't have people randomized to multigene versus single-gene testing. And what that does, it makes the resulting evidence base, whether it's efficacy, safety, or comparative cost-effectiveness, highly uncertain. So, the consequence of that has been uneven uptake around the world of next-generation sequencing panels. And so if we believe that next-gen sequencing panels are indeed effective for our patients, we really need to generate that comparative evidence around effectiveness and cost-effectiveness. So we can go to payers, whether it be single payer or a private insurer, to say, "Here are the comparative outcomes." And when I say that uptake has been uneven, uptake there's been actually plenty, as you know, publications around that uneven uptake, whether it be in Europe, in the United States, in Canada. And so we're really interested in trying to produce that evidence to create the type of deliberations that are needed to have these types of technologies accessible to patients. And part of those deliberations, of course, is the clinical, but also in some contexts, cost-effectiveness. And so, we really start from the perspective of, can we use our healthcare system data, our learning healthcare system, to generate that evidence in a way that emulates a randomized controlled trial? We won't be able to do these randomized controlled trials for various, like really important and and reasons that make sense, quite frankly. So how can we mimic or emulate randomized controlled trials in a way that allows us to make inference around those outcomes? And for my research lab, we usually think through how do we do causal inference to address some of those biases that are inherent in observational data. So in terms of advanced melanoma, we were really interested in this question because first of all, there have been no randomized controlled trials around next-gen sequencing versus single-gene testing. And secondly, these products, these ICIs, immune checkpoint inhibitors, and BRAF and MEK inhibitors, they are quite expensive. And so the question really becomes: are they effective? And if so, to what extent are they cost-effective? Do they provide a good reason to have information around value for money? Dr. Rafeh Naqash:So now going to the biology of melanoma, so we know that BRAF is one of the tumor-agnostic therapies, it has approvals for melanoma as well as several other tumor types. And in fact, I do trials with different RAF-RAS kinase inhibitors. Now, one of the things that I do know is, and I'm sure some of the listeners know, is the DREAMseq trial, which was a melanoma study that was an NCI Cooperative Group trial that was led by Dr. Mike Atkins from Georgetown a couple of years back, that did show survival benefit of first-line immunotherapy sequencing. It was a sequencing study of whether to do first-line BRAF in BRAF-mutant melanoma followed by checkpoint inhibitors, or vice versa. And the immune checkpoint inhibitors followed by BRAF was actually the one that showed benefit, and the trial had to stop early, was stopped early because of the significant benefit seen. So in that context, before we approach the question of single-gene versus multigene testing in melanoma, one would imagine that it's already established that upfront nivolumab plus ipilimumab, for that matter, doublet checkpoint inhibitor therapy is better for BRAF-mutant melanoma. And then there's no significant other approvals for melanoma for NRAS or KIT, you know, mucosal melanomas tend to have KIT mutations, for example, or uveal melanomas, for that matter, have GNAQ, and there's no targeted therapies. So, what is the actual need of doing a broader testing versus just testing for BRAF? So just trying to understand when you started looking into this question, I'm sure you kind of thought about some of these concepts before you delved into that. Dr. Dean Regier:I think that is an excellent question, and it is a question that we asked ourselves: did we really expect any differences in outcomes between the testing strategies? And what did the real-world implementation, physician-guided, physician-led implementation look like? And so, that was kind of one of the other reasons that we really were interested is, why would we go to expanded multigene panel sequencing at all? We didn't really expect or I didn't expect an overall survival a priori. But what we saw in our healthcare system, what happened in our healthcare system was the implementation in 2016 of this multigene panel. And this panel covered advanced melanoma, and this panel cost quite a bit more than what they were doing in terms of the single-gene BRAF testing. And so when you're a healthcare system, you have to ask yourself those questions of what is the additional value associated with that? And indeed, I think in a healthcare system, we have to be really aware that we do not actually follow to the ideal extent randomized controlled trials or trial settings. And so that's the other thing that we have to keep in mind is when these, whether it's an ICI or a BRAF MEK inhibitor, when these are implemented, they do not look like randomized controlled trials. And so, we really wanted to emulate not just a randomized controlled trial, but a pragmatic randomized controlled trial to really answer those real-world questions around implementation that are so important to decision making. Dr. Rafeh Naqash:Sure. And just to understand this a little better: for us in the United States, when we talk about multigene testing, we generally refer to, these days, whole-exome sequencing with whole-transcriptome sequencing, which is like the nuclear option of of the testings, which is not necessarily cheap. So, when you talk about multigene testing in your healthcare system, what does that look like? Is it a 16-gene panel? Is it a 52-gene panel? What is the actual makeup of that platform? Dr. Dean Regier:Excellent question. Yeah, so at the time that this study is looking at, it was 2016, when we, as BC Cancer—so British Columbia is a population right now of 5.7 million people, and we have data on all those individuals. We are one healthcare system providing health care to 5.7 million people. In 2016, we had what I call our "home-brew" multigene panel, which was a 53-gene panel that was reimbursed as standard of care across advanced cancers, one of them being advanced melanoma. We have evolved since then. I believe in 2022, we are using one of the Illumina panels, the Focus panel. And so things have changed; it's an evolving landscape. But we're specifically focused on the 53-gene panel. It was called OncoPanel. And that was produced in British Columbia through the Genome Sciences Centre, and it was validated in a single-arm trial mostly around validity, etc. Dr. Rafeh Naqash:Thank you for explaining that. So now, onto the actual meat and the science of this project. So, what are some of the metrics from a health economy standpoint that you did look at? And then, methodology-wise, I understand, in the United States, we have a fragmented healthcare system. I have data only from my institution, for that matter. So we have to reach out to outside collaborators and email them to get the data. And that is different for you where you have access to all the data under one umbrella. So could you speak to that a little bit and how that's an advantage for this kind of research especially? Dr. Dean Regier:Yeah. In health economics, we look at the comparative incremental costs against the incremental effectiveness. And when we think about incremental costs, we think not just about systemic therapy or whether you see a physician, but also about hospitalizations, about all the healthcare interactions related to oncology or not that a patient might experience during their time or interactions with the healthcare system. You can imagine with oncology, there are multiple interactions over a prolonged time period depending on survival. And so what we try to do is we try to—and the benefit of the single-payer healthcare system is what we do is we link all those resource utilization patterns that each patient encounters, and we know the price of that encounter. And we compare those incremental costs of, in this case, it's the multigene panel versus the single-gene panel. So it's not just the cost of the panel, not just the cost of systemic therapy, but hospitalizations, physician encounters, etc. And then similarly, we look at, in this case, we looked at overall survival - we can also look at progression-free survival - and ask the simple question, you know, what is the incremental cost per life-year gained? And in that way, we get a metric or an understanding of value for money. And how we evaluate that within a deliberative priority setting context is we look at safety and efficacy first. So a regulatory package that you might get from, in our case, Health Canada or the FDA, so we look at that package, and we deliberate on, okay, is it safe and is it effective? How many patients are affected, etc. And then separately, what is the cost-effectiveness? And at what price, if it's not cost-effective, at what price would it be cost-effective? Okay, so for example, we have this metric called the incremental cost-effectiveness ratio, which is incremental cost in the numerator, and in this case, life-years gained in the denominator. And if it is around $50,000 or $100,000 per life-year gained—so if it's in that range, this ratio—then we might say it's cost-effective. If it's above this range, which is common in oncology, especially when we talk about ICIs, etc., then you might want to negotiate a price. And indeed, when we negotiate that price, we use the economic evaluation, that incremental cost-effectiveness ratio, as a way to understand at what price should we negotiate to in order to get value for money for the healthcare system. Dr. Rafeh Naqash:Thank you for explaining those very interesting terminologies. Now, one question I have in the context of what you just mentioned is, you know, like the drug development space, you talked about efficacy and safety, but then on the safety side, we talk about all-grade adverse events or treatment-related adverse events—two different terminologies. From a healthcare utilization perspective, how do you untangle if a patient on a BRAF therapy got admitted for a hypoxic respiratory failure due to COPD, resulting in a hospitalization from the cost, overall cost utilization, or does it not matter? Dr. Dean Regier:We try to do as much digging into those questions as possible. And so, this is real-world data, right? Real-world data is not exactly as clean as you'd get from a well-conducted clinical trial. And so what we do is we look at potential adverse event, whether it's hospitalization, and the types of therapies around that hospitalization to try- and then engage with clinicians to try to understand or tease out the different grades of the adverse event. Whether it's successful or not, I think that is a real question that we grapple with in terms of are we accurate in delineating different levels of adverse events? But we try to take the data around the event to try to understand the context in which it happens. Dr. Rafeh Naqash:Thank you for explaining that, Dean. So, again to the results of this manuscript, could you go into the methodology briefly? Believe you had 147 patients, 147 patients in one arm, 147 in the other. How did you split that cohort, and what were some of the characteristics of this cohort? Dr. Dean Regier:So, the idea, of course, is that we have selection criteria, study inclusion criteria, which included in our case 364 patients. And these were patients who had advanced melanoma within our study time period. So that was 2016 to 2018. And we had one additional year follow. So we had three total years. And what we did is that we linked our data, our healthcare system data. During this time, because the policy change was in 2016, we had patients both go on the multigene panel and on the single-gene BRAF testing. So, the idea was to emulate a pragmatic randomized controlled trial where we looked at contemporaneous patients who had multigene panel testing versus single-gene BRAF testing. And then we did a matching procedure—we call it genetic matching. And that is a type of matching that allows us to balance covariates across the patient groups, across the multigene versus BRAF testing cohorts. The idea again is, as you get in a randomized controlled trial, you have these baseline characteristics that look the same. And then the hope is that you address any source selection or confounding biases that prohibit you to have a clean answer to the question: Is it effective or cost-effective? So you address all those biases that may prohibit you to find a signal if indeed a signal is there. And so, what we did is we created—we did this genetic matching to balance covariates across the two cohorts, and we matched them one-to-one. And so what we were able to do is we were able to find, of those 364 patients in our pool, 147 in the multigene versus 147 in the single-gene BRAF testing that were very, very similar. In fact, we created what's called a directed acyclic graph or a DAG, together with clinicians to say, “Hey, what biases would you expect to have in these two cohorts that might limit our ability to find a signal of effectiveness?” And so we worked with clinicians, with health economists, with epidemiologists to really understand those different biases at play. And the genetic matching was able to match the cohorts on the covariates of interest. Dr. Rafeh Naqash:And then could you speak on some of the highlights from the results? I know you did survival analysis, cost-effectiveness, could you explain that in terms of what you found? Dr. Dean Regier:We did two analyses. The intention-to-treat analysis is meant to emulate the pragmatic randomized controlled trial. And what that does is it answers the question, for all those eligible for multigene or single-gene testing: What is the cost-effectiveness in terms of incremental life-years gained and incremental cost per life-years gained? And the second one was around a protocol analysis, which really answered the question of: For those patients who were actually treated, what was the incremental effectiveness and cost-effectiveness? Now, they're different in two very important ways. For the intention-to-treat, it's around population questions. If we gave single-gene or multigene to the entire population of advanced melanoma patients, what is the cost-effectiveness? The per-protocol is really around that clinical question of those who actually received treatment, what was the incremental cost and effectiveness? So very different questions in terms of population versus clinical cost and effectiveness. So, for the intention-to-treat, what we found is that in terms of life-years gained is around 0.22, which is around 2.5 months of additional life that is afforded to patients who went through the multigene panel testing versus the single-gene testing. That was non-statistically significant from zero at the 5% level. But on average, you would expect this additional 2.5 months of life. The incremental costs were again non-statistically significant, but they're around $20,000. And so when we look at incremental cost-effectiveness, we can also look at the uncertainty around that question, meaning what percentage of incremental cost-effectiveness estimates are likely to be cost-effective at different willingness-to-pay thresholds? Okay? So if you are willing to pay $100,000 to get one gain of life-years, around 52.8% of our estimates, in terms of when we looked at the entire uncertainty, would be cost-effective. So actually that meets the threshold of implementation in our healthcare system. So it's quite uncertain, just over 50%. But what we see is that decision-makers actually have a high tolerance for uncertainty around cost-effectiveness. And so, while it is uncertain, we would say that, well, the cost-effectiveness is finely balanced. Now, when we looked at the population, the per-protocol population, those folks who just got treatment, we actually have a different story. We have all of a sudden around 4.5 or just under 5 months of life gained that is statistically significantly different from zero, meaning that this is a strong signal of benefit in terms of life-years gained. In terms of the changes in costs or the incremental costs, they are larger again, but statistically insignificant. So the question now is, to what extent is it cost-effective? What is the probability of it being cost-effective? And at the $100,000 per life-year gained willingness-to-pay, there was a 73% chance that multigene panel testing versus single-gene testing is cost-effective. Dr. Rafeh Naqash:So one of the questions I have here, this is a clarification both for myself and maybe the listeners also. So protocol treatment is basically if you had gene testing and you have a BRAF in the multigene panel, then the patient went on a BRAF treatment. Is that correct? Dr. Dean Regier:It's still physician choice. And I think that's important to say that. So typically what we saw in both in our pre- and post-matching data is that we saw around 50% of patients, irrespective of BRAF status, get an ICI, which is appropriate, right? And so the idea here is that you get physician-guided care, but if the patient no longer performs on the ICI, then it gives them a little bit more information on what to do next. Even during that time when we thought it wasn't going to be common to do an ICI, but it was actually quite common. Dr. Rafeh Naqash:Now, did you have any patients in this study who had the multigene testing done and had an NRAS or a KIT mutation and then went on to those therapies, which were not captured obviously in the single-gene testing, which would have just tried to look at BRAF? Dr. Dean Regier:So I did look at the data this morning because I thought that might come up in terms of my own questions that I had. I couldn't find it, but what we did see is that some patients went on to clinical trials. So, meaning that this multigene panel testing allowed, as you would hope in a learning healthcare system, patients to move on to clinical trials to have a better chance at more appropriate care if a target therapy was available. Dr. Rafeh Naqash:And the other question in that context, which is not necessarily related to the gene platform, but more on the variant allele frequency, so if you had a multigene panel that captured something that was present at a high VAF, with suspicion that this could be germline, did you have any of those patients? I'm guessing if you did, probably very low number, but I'm just thinking from a cost-effective standpoint, if you identify somebody with germline, their, you know, first-degree relative gets tested, that ends up, you know, prevention, etc. rather than somebody actually developing cancer subsequently. That's a lot of financial gains to the system if you capture something early. So did you look at that or maybe you're planning to look at that? Dr. Dean Regier:We did not look at that, but that is a really important question that typically goes unanswered in economic evaluations. And so, the short answer is yes, that result, if there was a germline finding, would be returned to the patient, and then the family would be able to be eligible for screening in the appropriate context. What we have found in economic evaluations, and we've recently published this research, is that that scope of analysis is rarely incorporated into the economic evaluation. So those downstream costs and those downstream benefits are ignored. And when you- especially also when you think about things like secondary or incidental findings, right? So it could be a germline finding for cancer, but what about all those other findings that we might have if you go with an exome or if you go with a genome, which by the way, we do have in British Columbia—we do whole-genome and transcriptome sequencing through something called the Personalized OncoGenomics program. That scope of evaluation, because it's very hard to get the right types of data, because it requires a decision model over the lifetime of both the patients and potentially their family, it becomes very complicated or complex to model over patients' and families' lifetime. That doesn't mean that we should not do it, however. Dr. Rafeh Naqash:So, in summary Dean, could you summarize some of the known and unknowns of what you learned and what you're planning in subsequent steps to this project? Dr. Dean Regier:Our North Star, if you will, is to really understand the entire system effect of next-generation sequencing panels, exome sequencing, whole genomes, or whole genomes and transcriptome analysis, which we think should be the future of precision oncology. The next steps in our research is to provide a nice base around multigene panels in terms of multigene versus single-gene testing, whether that be colorectal cancer, lung cancer, melanoma, etc., and to map out the entire system implications of implementing next-generation sequencing panels. And then we want to answer the questions around, “Well, what if we do exomes for all patients? What if we do whole genomes and transcriptomes for all patients? What are the comparative outcomes for a true tumor-agnostic precision oncology approach, accounting for, as you say, things like return of results with respect to hereditary cancers?” I think the challenge that's going to be encountered is really around the persistent high costs of something like a whole-genome and transcriptome sequencing approach. Although we do see the technology prices going down—the "$1,000 genome" or “$6,000 genome" on whatever Illumina machine you might have—that bioinformatics is continuing to be expensive. And so, there are pipelines that are automated, of course, and you can create a targeted gene report really rapidly within a reasonable turnaround time. But of course, for secondary or what I call level two analysis, that bioinformatics is going to continue to be expensive. And so, we're just continually asking that question is: In our healthcare system and in other healthcare systems, if you want to take a precision oncology approach, how do you create the pipelines? And what types of technologies really lend themselves to benefits over and above next-generation sequencing or multigene panels, allowing for access to off-label therapies? What does that look like? Does that actually improve patients? I think some of the challenges, of course, is because of heterogeneity, small benefiting populations, finding a signal if a signal is indeed there is really challenging. And so, what we are thinking through is, with respect to real-world evidence methods and emulating randomized controlled trials, what types of evidence methods actually allow us to find those signals if indeed those signals are there in the context of small benefiting populations? Dr. Rafeh Naqash:Thank you so much, Dean. Sounds like a very exciting field, especially in the current day and age where cost-effectiveness, financial toxicity is an important aspect of how we improve upon what is existing in oncology. And then lots more to be explored, as you mentioned. The last minute and a half I want to ask about you as an individual, as a researcher. There's very few people who have expertise in oncology, biomarkers, and health economics. So could you tell us for the sake of our trainees and early career physicians who might be listening, what was your trajectory briefly? How did you end up doing what you're doing? And maybe some advice for people who are interested in the cost of care, the cost of oncology drugs - what would your advice be for them very briefly? Dr. Dean Regier:Sure. So I'm an economist by training, and indeed I knew very little about the healthcare system and how it works. But I was recruited at one point to BC Cancer, to British Columbia, to really try to understand some of those questions around costs, and then I learned also around cost-effectiveness. And so, I did training in Scotland to understand patient preferences and patient values around quality of care, not just quantity of life, but also their quality of life and how that care was provided to them. And then after that, I was at Oxford University at the Nuffield Department of Population Health to understand how that can be incorporated into randomized control trials in children. And so, I did a little bit of learning about RCTs. Of course, during the way I picked up some epidemiology with deep understanding of what I call econometrics, what others might call biostatistics or just statistics. And from there, it was about working with clinicians, working with epidemiologists, working with clinical trialists, working with economists to understand the different approaches or ways of thinking of how to estimate efficacy, effectiveness, safety, and cost-effectiveness. I think this is really important to think through is that we have clinical trialists, we have people with deep understanding of biostatistics, we have genome scientists, we have clinicians, and then you add economists into the mix. What I've really benefited from is that interdisciplinary experience, meaning that when I talk to some of the world's leading genome scientists, I understand where they're coming from, what their hope and vision is. And they start to understand where I'm coming from and some of the tools that I use to understand comparative effectiveness and cost-effectiveness. And then we work together to actually change our methods in order to answer those questions that we're passionate about and curious about better for the benefit of patients. So, the short answer is it's been actually quite a trajectory between Canada, the UK. I spent some time at the University of Washington looking at the Fred Hutch Cancer Research Center, looking at precision oncology. And along the way, it's been an experience about interdisciplinary research approaches to evaluating comparative outcomes. And also really thinking through not just at one point in time on-off decisions—is this effective? Is it safe? Is it cost-effective?—not those on-off decisions, but those decisions across the lifecycle of a health product. What do those look like at each point in time? Because we gain new evidence, new information at each point in time as patients have more and more experience around it. And so what really is kind of driving our research is really thinking about interdisciplinary approaches to lifecycle evaluation of promising new drugs with the goal of having these promising technologies to patients sooner in a way that is sustainable for the healthcare system. Dr. Rafeh Naqash:Awesome. Thank you so much for those insights and also giving us a sneak peek of your very successful career. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Kimberly Shoaf, Professor of Public Health and the Director of the Rocky Mountains and High Plains Center for Emergency Public Health, discusses how a data-ready ecosystem for public health response can be beneficial; Ashley Cram, ASTHO Senior Analyst for Population Health, tells us about ASTHO's new web page dedicated to the support of Community Health Workers in island jurisdictions; and the Be Ready for Measles toolkit from CDC is online now. ASTHO Webinar: INSPIRE – Readiness - Building a Data-Ready Ecosystem for Public Health Response ASTHO Web Page: Tools That Support Community Health Worker Programs in Island Jurisdictions CDC Web Page: Be Ready for Measles Toolkit ASTHO Public Health Review Podcast Episode: Why We Serve – An Inside Look at Public Health AmeriCorps  

Dr. Sandra Hassink is joined by Dr. Asheley C. Skinner, Professor of Population Health at Duke University School of Medicine. Dr. Skinner also served as the methodologist on the Clinical Practice Guideline (CPG) for the Evaluation and Treatment of Children and Adolescents with Obesity. Together, they discuss the evidence behind the CPG. Related Resources: • Obesity CPG Homepage (tinyurl.com/52nz6m2m) • CPG Technical Report (I) (https://tinyurl.com/y7bnnsmc) • CPG Technical Report (II) (https://tinyurl.com/mv3s6eau)

In this episode, Dr. Mary Kim, Chief Medical Officer at Adventist HealthCare Physician Enterprise and VP of Population Health, shares how partnering with Culina Health is transforming access to personalized nutrition care. She highlights the role of digital platforms in closing care gaps, improving chronic disease outcomes, and advancing whole-person, community-focused healthcare.

In this episode of The Authority Company Podcast, Joe Pardavila speaks with Dr. Harm Scherpbier, physician and leading expert in healthcare IT, to explore the future of healthcare technology. Dr. Scherpbier, author of UN Vendor: Innovative Healthcare with a Diverse IT Stack, discusses the critical shift from single-vendor reliance to a more flexible, interoperable tech ecosystem.Key topics include:*The evolution from paper records to digital health systems and the ongoing challenges of interoperability.*How embracing third-party technologies—like AI-driven ambient clinical documentation—can enhance patient care, clinician efficiency, and cost-effectiveness.*The pitfalls of long-term vendor contracts and "all-in pricing," and strategies for healthcare systems to innovate without being locked into monolithic solutions.*Practical steps for healthcare leaders to diversify their IT stacks and foster a culture of innovation.Tune in for actionable insights on navigating the complexities of healthcare IT and preparing for a future where technology truly serves patients and providers alike.Dr. HARM SCHERPBIER is a physician and leading expert in health information technology with a career dedicated to improving healthcare through innovative IT solutions. Born in the Netherlands, Dr. Scherpbier earned his medical degree and a master's in medical informatics before moving to the United States, where he has served as a CMIO and health IT strategy advisor. He has partnered with organizations to implement clinical systems, data analytics, and population health solutions while teaching at Jefferson College of Population Health. A fellow of HIMSS and AMIA, Dr. Scherpbier is passionate about advancing modular and agile healthcare IT systems. When not transforming healthcare, he enjoys outdoor adventures with his family in Philadelphia, Pennsylvania.

The future of senior care is here—and it's powered by technology, personalized support, and the strength of strategic partnerships. In this special episode, we're joined by three visionary leaders transforming the way seniors receive care: Dr. Ali Khan, Chief Medical Officer for Medicare at Aetna; Dr. Marc Watkins, Chief Medical Officer at Kroger Health; and Brian Urban, Head of Commercial Strategy and Population Health at Best Buy Health. Together, they explore how technology, access to nutrition, human-centered design, and collaboration can solve some of the most pressing challenges in senior care. Dr. Khan emphasizes building ecosystems that blend tech with human touch, from broadband infrastructure to virtual PT with language support. Dr. Watkins highlights the role of pharmacists and retailers in delivering smarter, more accessible care through food scoring systems and telehealth integration. Brian Urban explains how smart home devices, personal tech support, and AI are helping seniors live safely and independently—while reducing social isolation and hospital visits. From personalized nutrition to AI-powered care delivery, tune in to discover how these cross-industry leaders are taking bold action to build a more connected, compassionate future for aging adults! Resources:  Connect and follow Dr. Ali Khan on LinkedIn. Learn more about Aetna, a CVS Health Company, on their LinkedIn and website. Connect and follow Dr. Marc Watkins on LinkedIn. Learn more about Kroger on their LinkedIn and website. Connect and follow Brian Urban on LinkedIn. Learn more about Best Buy Health on their LinkedIn and website.

Today's episode of the Faculty Factory Podcast is about the need for strong leadership in the face of uncertainty. It features a recording from a recent lecture led by Faculty Factory Podcast host Kimberly Skarupski, PhD, MPH. If you'd like to see any visuals from the lecture, please visit our Faculty Factory YouTube channel here: https://youtu.be/VxcRU1ZzGow  Dr. Skarupski is Associate Vice Provost, Leadership Development, in the Office of Faculty Affairs with UTMB Health in Galveston, Texas. She is a tenured Professor in the Department of Internal Medicine, Division of Geriatrics in the John Sealy School of Medicine and in the Department of Epidemiology in the School of Public and Population Health. The talk explores strategies for staying grounded, communicating with clarity, and supporting your postdocs through uncertain times. This lecture has been edited and repurposed to provide a friendly podcast listening experience. Learn more about the Faculty Factory: https://facultyfactory.org/ 

Parenthood is hard, and expensive. Over the course of 18 years, it costs nearly $300,000 to raise a child in the state of Connecticut. So is a $5000 baby bonus really going to inspire prospective parents to have children? Today, we talk about some of the Trump administration’s recent proposals to increase the birthrate. Ahead of Mother’s Day, we dig into solutions to supporting parents. We hear from parents who will share the ways they’d like to be supported throughout their parenthood journey. And we want to hear from you, what’s parenthood like right now? What support systems would you like to see? GUESTS: Sarah Donaldson: graduate student at Southern Connecticut State University Jessica Holzer: Associate Professor and Chair of the Department of Population Health and Leadership Malissa Griffith: Program Manager of Parents Connecting Parents and family engagement at the Connecticut Office of Early Childhood Support the show: http://wnpr.org/donateSee omnystudio.com/listener for privacy information.

Are you ready to discover how technology can revolutionize healthcare delivery? In this podcast hosted by Cognizant Product Director Chenny Solaiyappan, Best Buy Health Head of Population Health Brian Urban speaks on transforming patient care through innovative technology solutions. Brian shares insights on Best Buy Health's unique approach to enabling care through meaningful technological connections, revealing how they're reimagining healthcare for seniors and chronically ill populations.

We kicked off the program with four news stories we thought you'd like to know more about!Emily Sweeney, Cold Case Reporter for the Boston Globe, discussed the unsolved 1973 killings of Maureen Moynihan and her young daughter, Jennifer.Paula Fleming, Chief Marketing and Sales Officer and Chief Spokesperson for the Better Business Bureau of Eastern Massachusetts, Maine, Rhode Island & Vermont, checked in about the upcoming Real ID deadline and potential scams.What is the possible link between heart disease and household plastics? Dr. Leonardo Trasande, Professor of Pediatrics and Professor, Department of Population Health, at New York University Grossman School of Medicine explained.Nicole Narea, Senior Politics Writer at Vox, discussed President Trump's tariff shock fading on Wall Street.Listen to WBZ NewsRadio on the NEW iHeart Radio app and be sure to set WBZ NewsRadio as your #1 preset!

What if the biggest reason women stop life-saving treatment isn't the medication—but clinicians talk to them about it?In this eye-opening episode, I talk with Dr. Janeane Anderson, a powerhouse researcher and faculty member at the International Society for the Study of Women's Sexual Health, about the hidden reasons so many women stop taking critical medications like tamoxifen. It's not just about the side effects—it's about the silence surrounding them.We dig into her research on how poor communication, racial bias, trauma, and lack of sexual health conversations lead to lower adherence rates, especially for Black women. We also explore the idea of epistemic injustice—how patients are often dismissed, even when they know something is wrong. Janeane shares how this harm shows up in the room and what clinicians can do to build trust and improve care.From religious shame to relationship dynamics, sexual trauma, and systemic inequality, this conversation doesn't shy away from the messy, painful, and very real barriers women face in their health journeys. But we also talk about hope—what it looks like to listen better, ask different questions, and create safer spaces for patients to advocate for themselves.If you're a patient who's ever felt unheard, or a clinician who wants to do better, this one's for you.Highlights:Why Black women are disproportionately affected by advanced-stage breast cancer.The link between sexual dysfunction and stopping cancer treatment.How religion, shame, and duty shape sexual health after diagnosis.What epistemic injustice means and how it plays out in exam rooms.Simple but powerful questions doctors can ask to avoid retraumatizing patients.If this episode resonated with you, please hit subscribe, leave a review on Apple Podcasts, and share it with someone who needs to hear it. Let's change how we talk about women's health—together.Dr. Janeane N. Anderson Bio:Janeane N. Anderson is an Assistant Professor in the Department of Community and Population Health in the College of Nursing at the University of Tennessee Health Science Center (UTHSC) in Memphis, TN. Dr. Anderson completed postdoctoral research fellowships at Emory University and UTHSC. She earned a Ph.D. in Communication and a Master of Public Health degree from the University of Southern California.Dr. Anderson's research targets the relationship between patient-clinician communication practices and clinical and quality of life outcomes among Black adults with chronic health conditions, specifically breast cancer, HIV/AIDS, and vulvovaginal and pelvic pain.Past extramural funding from National Cancer Institute supported studies that explored patient-clinician communication, treatment adherence, and sexual health challenges among women with early-stage, HR+ breast cancer. Funding from the Washington DC Center for AIDS Research supported development of a shared decision-making tool to improve uptake of pre-exposure prophylaxis (PrEP) among Black sexual minority men; the Tennessee Department of Health funding supported development and implementation of a training for healthcare professional students to improve communication practices for PrEP education and counseling.Currently, she is the Co-PI of a $1.58 million industry-sponsored grant to investigate multilevel barriers to healthcare access and utilization among Black women with de novo metastatic breast cancer and those with increased risk for advanced breast disease in the U.S. Mid-South region.Dr. Anderson's professional activities also include developing faculty resources and university-level programming to address diversity, equity, and inclusion goals and objectives. She is frequently invited to give lectures on systems of oppression, patient-centered communication practices, and sensitive and socially...

Significant class-based health inequalities are also documented with in racial groups. It's time for national action to improve outcomes for all races and classes Now That's Real Talk!  www.kwaygospel.com

In today's episode, we explore some big questions about community health — and how hospitals and health care workers can help promote equitable health outcomes in their communities. The Community Health Needs Assessment, or CHNA, is a  powerful tool for promoting health equity, says Leslie Marshburn, Vice President of Strategy & Population Health at Grady Health System. “We want to be hearing directly from the individuals that we serve — what they believe their community health needs are,” Marshburn says. The information is coupled with public data, “ideally at the most granular level, like the census track or zip code. And so those national data sets can help inform what the needs are, and then layering that with the community voice through your primary data collection and synthesizing all of that helps you identify your priorities.” When it comes to improving health outcomes in communities, it's also critical that health care providers understand health disparities, says Dr. Maura George, an associate professor in the Department of Medicine and an internist at Grady Memorial Hospital in Atlanta, where she also serves as Medical Director of Ethics.  “I think clinicians who don't know how to recognize disparities are going to perpetuate them, and we can all do that unintentionally,” George says. “I think knowing our own internalized bias, implicit bias is important, because you have to realize how that can interact in the patient care space.” Marshburn and George joined Movement Is Life's summit as workshop panelists, and spoke with steering committee member Dr. Zachary Lum for this podcast episode. Never miss an episode – be sure to subscribe to The Health Disparities podcast from Movement Is Life on Apple Podcasts, YouTube, or wherever you get your podcasts.

What if a simple conversation in the emergency room could reveal who's most at risk for PTSD before symptoms even begin? Katharina Schultebraucks, PhD, shares her innovative work on using machine learning to forecast mental health outcomes and explains how AI could revolutionize how we detect, prevent, and treat psychiatric disorders. Dr. Schultebraucks is Co-Director of the Computational Psychiatry Program and Associate Professor in the Department of Psychiatry and Population Health at NYU Grossman School of Medicine.

Dr. Joseph Ladapo is a Nigerian-American physician and health policy researcher currently serving as the Surgeon General of Florida since 2021. Born in Nigeria, he immigrated to the United States at the age of 5 with his family when his father, a microbiologist, came to continue his studies. Dr. Ladapo completed his undergraduate studies at Wake Forest University, where he was a decathlete and captain of the varsity track and field team. He then went on to earn his MD from Harvard Medical School and a PhD in Health Policy from Harvard Graduate School of Arts and Sciences. He completed his clinical training in internal medicine. Throughout his career, Dr. Ladapo has held various academic positions. He served as a faculty member in the Department of Population Health at NYU School of Medicine and as a Staff Fellow at the U.S. Food and Drug Administration (FDA). Prior to his current role, he was an Associate Professor at the David Geffen School of Medicine at UCLA. Dr. Ladapo's research focuses on clinical trial interventions and reducing the population burden of cardiovascular disease. His work has been funded by the National Institutes of Health (NIH) and the Robert Wood Johnson Foundation, and his studies have been published in leading medical journals. In recent years, Dr. Ladapo has gained prominence for his bold stance on COVID-19 mitigation measures, in which he opposed mask and vaccine mandates, questioned the safety of COVID-19 vaccines, and approved alternative treatments. Currently, Dr. Ladapo serves as a Professor of Medicine at the University of Florida College of Medicine in addition to his role as Florida's Surgeon General. He is married and has three young children.

I sit down with Dr Aasma Shaukat, Gastroenterologist and Professor of Population Health, who is also trained in Epidemiology and Clinical Research, and Director of GI Outcomes Research at NYU Langone Health, Grossman School of Medicine.  We talk about progress in healthcare fields including gastroenterology.  We talk microbiome (I compared my digestive tract to the ocean).  We did talk colonoscopy prep in quite a bit of detail.  We also talk about screening rates in the NYC area< C5 and how fortunate we are to work and live in an area that really tries to be inclusive and proactive.  Gastroenterology has incorporated AI tools, so far in polyp detection, but also summarizing patient history and creating a whole picture, which is also helpful in oncology and more.  Note that this was originally recorded just after the New Year in early January.  

Visionary healthcare leaders from The Permanente Medical Group, UC Davis Health, UNC Health, Summit Medical Group and Navina joined Eric Glazer to explore how artificial intelligence transforms clinical workflows and enables better value-based care. Discover how AI-driven chart prep, ambient scribe technology, and risk models streamline provider workflows, improve patient outcomes, and reduce clinician burnout. From overcoming implementation roadblocks to building cross-functional frameworks that promote trust and equity, this episode is packed with strategic insights and real-world success stories you can apply at your organization. Panelists Include: Brian Hoberman, MD, EVP & CIO, The Permanente Medical Group Reshma Gupta, MD, Chief of Population Health and Accountable Care, UC Davis Health Ram Rimel, Manager of Data Science Engineering, UNC Health Eric Penniman, D.O. Executive Medical Director, Summit Medical Group Dana McCalley, VP of Value-Based Care, Navina https://www.brightspotsinhealthcare.com/events/the-new-physician-playbook-ai-workflows-value-based-care-in-action/#url This episode is sponsored by Navina Navina is the clinician-first AI copilot for value-based care. Recently named Best in KLAS for clinician digital workflows, Navina turns fragmented patient data into actionable clinical insights right at the point of care. Natively integrated into the clinical workflow, their AI copilot helps improve risk adjustment, quality metrics, and population health – while significantly easing the administrative burden. Navina has earned the trust of more than 10,000 clinicians and care team members across 1,300 clinics, from some of the leading value-based care organizations in the country like Privia Health, Agilon Health, and Millennium Physician Group. About Bright Spots in Healthcare Bright Spots in Healthcare is produced by Bright Spots Ventures Bright Spots Ventures brings healthcare leaders together to share working solutions or "bright spots" to common challenges. We build valuable and meaningful relationships through our Bright Spots in Healthcare podcast, webinar series, leadership councils, customized peer events, and sales and go-to-market consulting. We believe that finding a bright spot and cloning it is the most effective strategy to improve healthcare in our lifetime. Visit our website at www.brightspotsinhealthcare.com

In this episode, Dr Elle Wadsworth speaks to Dr Sandra Jumbe from the School of Social and Health Sciences at Millenium University in Malawi and the Wolfson Institute of Public Health Queen Mary, and Dr Chris Newby from the Medical School at the University of Nottingham. Sandra and Chris discuss their findings from a systematic review and meta-analysis on factors associated with adolescent substance use in Africa between 2000 and 2020. · What do we already know about adolescent use in Africa and why this review was needed [01:40]· The headline findings of the review [03:50]· What the consolidation of findings in this topic area will achieve [05:58]· The themes that came out of the ‘non-familial' category of factors associated with adolescent substance use [09:00]· The main themes that came out of the ‘socioeconomic or environmental' category of factors associated with adolescent substance use [10:05]· The regional differences in the drugs consumed across Africa [12:10]· What drugs are captured in standardised surveys [14:29]· The experience of doing systematic reviews and meta-analyses [15:20]About Sandra Jumbe: Dr Jumbe is a health psychologist currently working as a senior lecturer in research at Millennium University in Blantyre Malawi and a health researcher at the Wolfson Institute of Population Health at Queen Mary University of London. She is also an African Research Initiative for Scientific Excellence (ARISE) fellow with the African Academy of Sciences. She is an expert in behavioural science, enabling her to set the foundations for evidence-based work that informs development of effective interventions and policy decisions to improve human health. She has worked in both clinical and academic settings in primary care and mental health. Dr Jumbe's long term aspiration is to expand understanding of global mental health and substance use, by advancing research niched on youth mental health in Africa, while training fellow young African scientists. She is also a mental health advocate, passionate about improving mental health literacy at grassroots level using community engagement and culturally sensitive approaches.About Chris Newby: Dr Newby is a senior medical statistician at the Research Knowledge Exchange, at the Medical School at the University of Nottingham. He has worked in NIHR Biomedical Research Units, Clinical Trial Units and is currently a senior quantitative advisor at the Research Support Service Leicester Hub and Partners. His interests are Respiratory, Mental Health and Equality Diversity and Inclusion in Health Research. Sandra, Chris nor Elle have any conflicts of interest to declare.Original article: A systematic review and meta-analysis of factors associated with adolescent substance use in Africa, 2000 to 2020: https://doi.org/10.1111/add.70023The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

An interview with Jeff Jeran, Senior Director at Power Wellness. And I think that's, that's what makes a medical fitness center so special. It's just, it's a community very similar to group exercise. The reason why group exercise is so successful is it builds a tribe, and everyone is part of that, and hold each other kind of accountable when they show up. So I think that's, that's kind of the big part of what makes medical fitness successful.Jeff JeranMedical fitness callingMedical fitness reaching the 80%Medical and commercial fitnessMobile app connecting members and physiciansIntegrating into the electronic medical recordExpanding access to medical fitnessFinding a fitness center that meets your needs Building a community in a medical fitness centerhttps://www.movetolivemore.com/https://www.movetolivemore.com/bookhttps://www.linkedin.com/company/move-to-live-more@MovetoLiveMore

In this episode of Mavericks in Healthcare, hosts Ajay Mody and Asher Perzigian sit down with trailblazing leader Beth Dolan, Dean of the College of Health at Lehigh University. Beth isn't just rethinking healthcare education—she's turning it on its head. From championing interdisciplinary learning to weaving data science into the fabric of public health, Beth shares how Lehigh is preparing students to tackle today's most urgent health challenges. Discover how the College's bold initiatives—like its cutting-edge Population Health program and hands-on community-based research—are shaping a new kind of health professional. Plus, Beth opens up about the critical role of mental health in academia and what it really means to build a truly supportive student experience. If you're curious about the future of healthcare, education, and innovation, this conversation is a must-listen. Beth Dolan is on a mission—and she's inviting the next generation to lead the way.

In this episode, Dr. Ruchi Talwar, Medical Director of Episodes of Care Population Health at Vanderbilt Health, joins Jakob Emerson to discuss how provider-led bundled payment programs are improving outcomes, reducing costs, and delivering value for both employers and patients. She shares insights into Vanderbilt's innovative “My Health Bundles” and their real-world success in reshaping specialty care.

In this episode, Dr. Ruchi Talwar, Medical Director of Episodes of Care Population Health at Vanderbilt Health, joins Jakob Emerson to discuss how provider-led bundled payment programs are improving outcomes, reducing costs, and delivering value for both employers and patients. She shares insights into Vanderbilt's innovative “My Health Bundles” and their real-world success in reshaping specialty care.

In this episode of the Brain & Life Podcast, co-host Dr. Katy Peters is joined by Hide Harashima, dad, advocate, and founder and president of Love4Lucas Foundation. He discusses creating the Love4Lucas Foundation in honor of his son Lucas, who was diagnosed with diffuse intrinsic pontine glioma (DIPG). Dr. Peters is then joined by Dr. Paul Fisher, Professor of Neurology and Pediatrics, and by courtesy, Neurosurgery and Epidemiology and Population Health, Beirne Family Professor of Pediatric Neuro-Oncology, Dunlevie Family University Fellow in Undergraduate Education at Stanford University, and Editor-in-Chief of The Journal of Pediatrics. Dr. Fisher explains DIPG and other similar cancers, discusses treatment options, and what new research is being done today.   Additional Resources Love4Lucas Patients and Their Loved Ones Find New Roles as Advocates After Diagnoses Lawyer and Model Who Survived Brain Tumors Focuses on Giving Back   Other Brain & Life Podcast Episodes Actor Craig Russell on Staying Positive during his Brain Tumor Diagnosis Lawyer, Model Victoria Vesce Uses Her Platform for Brain Tumor Advocacy BMX Athlete Josh Perry's Perseverance Living with Brain Tumors We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media: Hide Harashima @love4lucasfoundation; Dr. Paul Fisher @stanfordchildrens Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

In this episode, Jewel Mullen, MD, MPH, MPA, and Dallas Nelson, MD, CMD, FACP discuss overcoming barriers to RSV vaccine uptake in post-acute and long-term care facilities, including:How to incorporate the latest RSV vaccination recommendations into clinical practicePractical strategies for navigating insuranceEffective and empathetic methods of addressing vaccine hesitancy.  Presenters:Jewel Mullen, MD, MPH, MPAAssociate Dean for Health EquityAssociate Professor of Population Health and Internal MedicineUniversity of Texas at Austin Dell Medical SchoolAustin, TexasDallas Nelson, MD, CMD, FACPProfessor of MedicineDivision of Geriatrics and AgingUniversity of RochesterMedical DirectorUR Medicine Geriatrics GroupRochester, New YorkLink to full program: https://bit.ly/4lrwa5uFollow along with the slides: https://bit.ly/3RdWAKeGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

Despite affecting more Americans than diabetes, substance use is often left out of routine medical care. In this episode, NYU Langone Health's Jennifer McNeely, MD—a clinician investigator, primary care and addiction medicine physician—explains why that must change. From the surprising history behind addiction's exclusion from mainstream medicine to the innovative screening tools shaping the future of care, this conversation is a must-listen for anyone interested in addiction care and healthcare policy.Jennifer McNeely, MD, is an Associate Professor of Medicine and Population Health at NYU Grossman School of Medicine and co-director of the Section on Tobacco, Alcohol, and Drug Use.

The Smart 7 is an award winning daily podcast, in association with METRO that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 17 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:Guests: Barry “Butch” WIlmore - NASA Astronaut, US Navy Captain (retired) Suni Williams - NASA Astronaut and ISS Commander for Mission 32 / 33 Nick Hague - NASA Astronaut and US Space Force ColonelRabea Rogge - German Astronaut and first German woman in space Will Guyatt - The Smart 7's Tech Guru Doctor Steven Woolf - Professor of Family Medicine and Population Health at Virginia Commonwealth University,Anna-Katharina Hornidge - Professor for Global Sustainable Development at the University of BonnBenjamin Jones - Economist at Northwestern UniversityProfessor Liz Bentley - The Royal Meteorological SocietyProfessor Tara Spires-Jones - President of the British Neuroscience Association Blake Shook - Beekeeper and the Founder of Desert Creek HoneyJuliana Rangel - Associate Professor of Apiculture at A&M University in TexasSimon Saville - Butterfly Conservation Mark Field - Pembrokeshire Farmer and Twin Donkey owner Dr Andrew Clemence - Veterinary Surgeon Contact us over @TheSmart7pod or visit www.thesmart7.com or find out more at www.metro.co.uk This Episode is presented by Mike Wooller, written by Liam Thompson and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

Relative to peer countries, the United States has higher mortality rates from most major causes of death. Americans live shorter, sicker lives than their counterparts in other countries Now That's Real Talk! www.kwaygospel.com  

Shanghai has become a pioneering city in China to introduce standards regulating smoking in outdoor public spaces. Could this be the start of a nationwide shift? China aims to cut adult smoking from 24% to 20% by 2030, but with cigarette sales still climbing, how challenging is that goal? Can this policy truly make an impact, or will deep-rooted smoking culture stand in the way?Host Tu Yun joins Dr. Xiongfei Pan, a Professor of Epidemiology and Population Health at the West China Second University Hospital, Sichuan University, Dr. Liu Baocheng, the Director of the Center for International Business Ethics, University of International Business and Economics, and Dr. Lauren Johnston, an associate professor of the China Studies Centre, University of Sydney, Australia to check for answers to these and more at the Chat Lounge.

What makes addiction treatment truly effective? Behavioral scientist Charles Neighbors, MBA, PhD, shares groundbreaking research on the importance of therapeutic relationships, harm reduction, and human connection—love!—in treating substance use disorders. Dr. Neighbors is an Associate Professor in the Departments of Population Health, and Psychiatry at NYU Grossman School of Medicine.

THIS TIME ON CODE WACK!   How is Ireland's plan for single-tier, universal health care, known as Sláintecare, funded? Is it sustainable long term? What improvements has the nation's healthcare system seen so far – and what can America learn from this? To find out, we spoke to Dr. Sara Burke, associate professor and director of the Centre for Health Policy and Management in Trinity College Dublin's School of Medicine.  She is the Principal Investigator of a research project entitled 'Health system foundations for Sláintecare implementation in 2020 and beyond …' and Co-Director of  SPHeRE, Ireland's national research training program for population health, policy and health services research. Her research interests include health policy, inequities in health, healthcare access and the politics of health reform. This is the second of two episodes with Dr. Burke. Check out the Transcript and Show Notes for more! And please keep Code WACK! on the air with a tax-deductible donation at heal-ca.org/donate.

In this special HIMSS25 recap episode of The Dish on Health IT, host Tony Schueth, CEO of Point-of-Care Partners (POCP), is joined by co-hosts Brian Bamberger, POCP's Life Sciences Lead, and Vanessa Candelora, Senior Consultant and Program Manager of the HL7 Gravity Project. Together, they break down the biggest themes from the conference, covering interoperability, artificial intelligence (AI), FHIR adoption, and the growing focus on improving data quality in healthcare innovation.HIMSS25 once again proved to be a crucial gathering of healthcare leaders, vendors, and policymakers, drawing nearly 28,000 attendees. Vanessa notes the continued focus on interoperability and trust, with a clear divide between experienced stakeholders refining their strategies and newcomers trying to grasp the fundamentals of FHIR. Brian, a HIMSS veteran, points out that first-time attendees often struggle with the complexity of both the conference itself and the discussions around health IT's latest advancements, particularly AI and its real-world applications.To add perspectives from the conference floor, Tony introduces a series of interviews with HIMSS25 attendees and industry leaders, including Anna Taylor, Associate Vice President, Population Health and Value-Based Care of MultiCare, Erin Weber, Chief Policy & Research Officer, CAQH, Mariann Yeager, CEO, The Sequoia Project, Matthew Holt, Founder/Writer of The Health Care Blog, and Lynne Nowak, Chief Data and Analytics Officer. Each interview provides insights into the real-world implementation of interoperability and FHIR, the evolving use of AI, and how data privacy and governance are shaping health IT strategy.FHIR adoption was one of the topics covered in the interviews. Some, like Mariann Yeager and Erin Weber, expressed optimism about FHIR's expanding role in clinical data exchange, while others, such as Anna Taylor, highlighted persistent scalability challenges and limited adoption for administrative functions like prior authorization. Matthew Holt offered a broader view on data exchange, arguing that while data mobility has improved, the real challenge is how organizations actually use and integrate that information. Vanessa underscores that while FHIR is gaining traction globally, large-scale implementation remains a work in progress. The panel agrees that translating theoretical frameworks into real-world adoption is the next crucial step.AI was another dominant topic, with a mix of enthusiasm and skepticism surrounding its potential. The HIMSS interviewees discuss AI's growing role in streamlining administrative workflows, summarizing patient records, and enabling ambient listening for clinical documentation. However, as Brian bluntly puts it, the “magic” of AI is still far from reality—many tools promise seamless EHR integration but lack the ability to write back into clinical systems, requiring manual intervention. Lynne Nowak and others emphasized that AI's effectiveness is directly tied to data quality—bad inputs will only lead to bad outputs. The consensus? AI has real potential to enhance workflows but cannot replace clinicians, and health IT leaders must focus on governance, usability, and ensuring AI supports, rather than replaces, human decision-making.As the conversation wraps up, Vanessa highlights the critical role of policy and strategic innovation in shaping the next wave of health IT progress. With new regulatory shifts and uncertainty around TEFCA, organizations must stay agile while ensuring that patient privacy, data integrity, and consent management remain top priorities. Brian brings the discussion back to life sciences, stressing the importance of leveraging patient insights and real-world data to drive treatment adherence and improve outcomes.HIMSS25 reinforced that while FHIR, AI, and interoperability remain hot topics, the industry is now at a critical inflection point—shifting from theory to execution. Organizations must filter out hype, focus on data quality, and build scalable solutions that improve both clinical and administrative functions.For those who couldn't attend HIMSS25 or want a deeper dive into what's next for health IT, this episode provides a comprehensive breakdown of the major takeaways. Subscribe to The Dish on Health IT on Apple Podcasts, Spotify, or your preferred platform. The podcast is also available on HealthcareNOW Radio. Full video versions are also available on POCP's YouTube channel. As always, health IT is a dish best served hot. 

March 18, 2025: Today on TownHall, Sue Schade, Principal at StarBridge Advisors, talks with Sonney Sapra, SVP and CIO at Samaritan Health Services. Sonney discusses his nearly four-year journey at Samaritan Health, detailing the organization's focus on technological innovation, financial sustainability, and population health. Why move to a fully cloud-based infrastructure? How can AI and ambient listening technologies transform healthcare? Sonny shares insights into these questions and more, including integrating health plan data to improve patient outcomes. He also delves into workforce management in a remote and hybrid environment, and emphasizes the importance of understanding organizational needs in vendor partnerships. Finally, Sonny discusses his future role as a TownHall moderator in 2025 and his passion for sharing knowledge within the CIO community. Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: This Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

This episode, recorded live at the Becker's Healthcare 12th Annual CEO + CFO Roundtable, features Dr. Arshad K. Rahim, CMO of Population Health and Clinically Integrated Network at Mount Sinai Health System. Dr. Rahim shares his perspectives on AI's role in population health, the challenges of value-based care, and the evolving relationship with payers. He also discusses the importance of data, patient engagement strategies, and the future of healthcare in 2025.In collaboration with R1.

Mental health is no longer optional in the workplace - it's essential. In this episode of Side Affects, hosts Kenzie McEvily and Dave Homan sit down with Tiffany Kuck, Director of Population Health at McGohan Brabender, to discuss how Mental Health First Aid Training is transforming corporate wellness. From skyrocketing stress levels to legal landmines in wellness programs, we uncover the biggest challenges employers face - and the strategies that actually work. Plus, find out how some companies are saving on healthcare costs, boosting productivity, and staying legally compliant while creating a healthier, happier workforce. Tune in for expert insights, real-world success stories, and actionable takeaways!

J.T. Lane, ASTHO Senior Vice President for Population Health and Innovation at ASTHO, tells us how the HIMSS Global Health Conference and Exhibition is pushing health data modernization forward; Alex Wheatley, ASTHO Senior Director of Island Support, explains why this week is so important for the Island Areas; and ASTHO's Board of Directors will meet on Monday, March 10. HIMSS Global Health Conference & Exhibition Web Page ASTHO News Release: State and Territorial Health Leaders Convene on Capitol Hill to Advocate for Sustained Funding  

Health plan leaders from Cambia Health Solutions, Highmark Health and League share strategies for driving consumer engagement, improving health outcomes, and optimizing payer-provider relationships. Learn how health plans can shift from broad segmentation strategies to truly personalized, member-centric healthcare by harnessing data, AI, and digital transformation.     Learn how health plans are using AI-driven insights to deliver tailored interventions.

In this episode, Anna Taylor, Associate Vice President of Population Health and Value-Based Care at MultiCare Connected Care, discusses the evolving role of data in transforming healthcare. She shares insights on overcoming data interoperability challenges, MultiCare's partnership with Tuva Health, and how leveraging big data is key to improving patient outcomes and operational efficiency.

In this week's enlightening episode of the Faculty Factory Podcast, we explore finding satisfaction in our careers. We discuss how we measure and perceive this satisfaction, as well as examine its connection to success—or the lack thereof. Joining us for this introspective discussion is our first-time guest, Brian Downer, PhD. With the University of Texas Medical Branch (UTMB), Dr. Downer is an Associate Professor in the Department of Population Health and Health Disparities in the School of Public and Population Health. He is also the Director of the Rehabilitation Sciences Graduate Program and a Program Director for Population Health Sciences Program. Dr. Downer is a Gerontologist by training. If you would like to read the article referenced by Dr. Downer in this podcast, you can find the 2023 article from the Harvard Business Review titled "Why Success Doesn't Lead to Satisfaction" here: https://hbr.org/2023/01/why-success-doesnt-lead-to-satisfaction. Where does satisfaction start? Perhaps with a shift in your mindset, as we learn from Dr. Downer and the article he references above throughout today's conversation. As outlined in this podcast, that mindset shift is about finding satisfaction “because,” not “when.” Essentially, if you wait until you achieve something to believe that you will derive satisfaction from it, that fulfillment may never come, or it may be very short-lived, leaving you wanting so much more. Finding joy in the journey, rather than in the destination, can be the key to achieving the satisfaction that you might otherwise find missing as your career milestones, laurels, achievements, and “successes” accumulate. How to go about capturing that joy is at the heart of this discussion. Visit the Faculty Factory website for more resources: https://facultyfactory.org/.

Which cooking oils are best for your health?Listener Sarah got in touch after seeing claims on social media that more expensive oils are better for you than regular vegetable, or rapeseed oil. And listener Kamal sent us a voicenote asking about coconut and avocado oil - both touted as healthier alternatives to other types of oil. Are they worth the extra cost? And what about health concerns if certain oils are overheated? To get the answers Greg is joined by Professor of Population Health and Nutrition at the University of Cambridge, Nita Forouhi. Together they deep-dive into the studies and evidence, finding out what compounds constitute a healthy oil and giving advice on what we should be looking out for on the bottle. All of our investigations start with YOUR suggestions. If you've seen an ad, trend or wonder product promising to make you happier, healthier or greener, email us at sliced.bread@bbc.co.uk OR send a voice note to our WhatsApp number, 07543 306807PRESENTER: GREG FOOTPRODUCERS: SIMON HOBAN AND PHIL SANSOM

Piper speaks with Dr. Pouya Dini about UC Davis producing equine embryos by in vitro fertilization. Dr. Anna Dunaway of Purina Animal Nutrition talks about equine weight management strategies owners can use to have a meaningful impact on weight and body condition score. Dr. Gus Cothran also joins to talk about new research on the Y chromosome that will allow geneticists to trace the paternal line in horses. Brought to you by Taylor, Harris Insurance Services.Host: Piper Klemm, publisher of The Plaid HorseGuest: Dr. Pouya Dini is an associate professor at the Department of Population Health and Reproduction and the chief of the Equine Reproduction Service at the School of Veterinary Medicine at the University of California. He is a Diplomate of the European College of Animal Reproduction and the American College of Theriogenologists. Pouya holds two PhD degrees. The first PhD he obtained was a collaboration between Azad University and the University of Ghent, Belgium, and the second PhD was a collaboration between the University of Ghent and Gluck Equine Research Center at the University of Kentucky. His current research interests include the pathophysiology of the equine placenta and embryo development at the genomic level. Pouya is also the Director of the Veterinary Assisted Reproduction Laboratory, a research facility and a national embryo service provider for breeders and veterinarians located at the Department of Population Health and Reproduction at the School of Veterinary Medicine at UC Davis. Guest: Dr. Anna Dunaway is a Nutritionist on the Equine Technical Solutions team at Purina Animal Nutrition. Her Ph.D. research at the University of Nebraska focused on the use of high fat diets and manipulating the microbial community in the gut. Now at Purina, Dr. Dunaway's role includes bringing innovative solutions like the Equine MQ™ Platform from the research team out to the field.Guest: Dr. Gus Cothran was born and raised in Texas and graduated from North Texas State University where he obtained his BS and MS degrees in Biology. He then received his Ph.D. in genetics from the University of Oklahoma. Dr. Cothran worked at the University of Georgia's Savannah River Ecology Laboratory, then at the Southwest Foundation for Biomedical Research where he worked on the genetics of horses. From there, he moved to the University of Kentucky and was the Director of the Equine Parentage Testing and Research Laboratory, and Research Professor in the Department of Veterinary Science. In 2006, Dr. Cothran moved to Texas A&M University, where he was a Clinical Professor in the Department of Veterinary Integrative Biosciences. In 2016, Dr. Cothran retired but was named as an Emeritus Professor and he remains active in research activities. Dr. Cothran was a four-time Chair of the International Society of Animal Genetics standing committee for Thoroughbred DNA Typing Standardization, and a past chair of the Equine Standing Committee.Title Sponsor: Taylor, Harris Insurance ServicesSubscribe To: The Plaid Horse MagazineSponsors: Show Strides Book Series, Good Boy, Eddie and Geoff Teall on Riding Hunters, Jumpers and Equitation: Develop a Winni

Hey lady! This week, Dr. Dom and Terri welcome Dr. Maisha Standifer, Director of Population Health, The Satcher Health Leadership Institute at Morehouse School of Medicine to offer fresh information about HIV, AIDS, the trends she's seeing in sexually transmitted disease infection rates and what Black women need to know about keeping themselves safe and healthy.Dr. Standifer is a powerhouse of a woman and offers grounded perspective on the real issues that the Black community face in regards to HIV transmission and AIDS. The truth of the matter is that despite HIV/AIDS being known in the community for more than 40 years the stigma has transferred from white gay men to Black women and so much of that is because of a lack of information.In fact, 50 percent of new HIV cases are Black women. Dr. Standifer doesn't sugarcoat the facts about the fact if you are sexually active you are HIV possible. Armed with that knowledge, she offers solutions for prevention, resources for care should you contract the infection, and hope for a future where HIV and AIDS is eradicated from the community.Tune into a powerful conversation chock full of valuable information. This is your one precious life, lady, treat it with the best care! Quote of the Day:“Understand others and their experiences as you talk and interact with them.” - Unknown  Wisdom Wednesdays with TerriCultivating H.E.R. Space Sanctuary  Where to find Satcher Health:Website: Morehouse School of MedicineWebsite: Satcher Health Leadership InsituteInstagram: @satcherhealthFacebook: Satcher HealthLinkedIn: Satcher Health Leadership Institute  Resources:Dr. Dom's Therapy PracticeBranding with TerriMelanin and Mental HealthTherapy for Black Girls Psychology TodayTherapy for QPOC  Where to find us:Twitter: @HERspacepodcastInstagram: @herspacepodcastFacebook: @herspacepodcastWebsite: cultivatingherspace.com